Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Diabetic Retinopathy - A US Market Report

2448.67

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£2,448.67

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

United States

Published

1 June 2010

Number of Pages

325

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Global Industry Analysts

File Format

-

The US Diabetic Retinopathy Market will Exceed $540 Million by 2015. Diabetic retinopathy is a fashion of eye disease that occurs in people suffering from diabetes, governing to severe vision loss, and in some cases, even total blindness. Diabetic retinopathy is a collective entitle given to diverse abnormalities associated with retinal small blood vessels that are inflicted by diabetes.

Vision loss due to diabetic retinopathy is caused by pair conditions: Diabetic Macular Edema is a form of non-proliferative diabetic retinopathy where fluid enters the macula, causing it to swell and thus tend the vision blurred. Proliferative Diabetic Retinopathy is the final stage of diabetic retinopathy, in which place problems with circulation of blood cause certain retinal areas to change to ischemic (deprived of oxygen). Proliferative Diabetic Retinopathy is a major create of vision loss in patients with diabetic retinopathy.

According to Global Industry Analysts, drug therapy as antidote to diabetic retinopathy, however, is no longer a dubious proposition. Drugs of that kind as Arxxant (Eli Lilly), Atacand (Astra Zeneca), Lucentis (Genentech/Novartis), Avastin (Genetech/Roche) and Dexamethasone are every one of in their late stage development; and some of these drugs are expected to enter the market in the next few years. These drugs, when approved, would open new doors for the treatment of diabetic retinopathy, a disease that is soon being managed only by preventive measures and surgical intervention.

This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Global Industry Analysts ©

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£2,448.67

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings